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Objective: Current prevention and/or treatment options for respiratory syncytial virus
(RSV) infections are limited as no vaccine is available. Prophylaxis with palivizumab is very
expensive and requires multiple intramuscular injections over the RSV season. Here we
present proof-of-concept data using nebulized palivizumab delivery as a promising new
approach for the prevention or treatment of severe RSV infections, documenting both
aerosol characteristics and pulmonary deposition patterns in the lungs of lambs.
Design: Prospective animal study.
Setting: Biosecurity Control Level 2-designated large animal research facility at the
Murdoch Children’s Research Institute, Melbourne, Australia.
Subjects: Four weaned Border-Leicester/Suffolk lambs at 5 months of age.
Interventions: Four lambs were administered aerosolized palivizumab conjugated to Tc-
99m, under gaseous anesthesia, using either the commercially available AeroNeb Go® or
the investigational HYDRA device, placed in-line with the inspiratory limb of a breathing
circuit. Lambs were scanned in a single-photon emission computed tomography (SPECT/
CT) scanner in the supine position during the administration procedure.
Measurements and Main Results: Both the HYDRA and AeroNeb Go® produced
palivizumab aerosols in the 1–5 µm range with similar median (geometric standard
deviation and range) aerosol droplet diameters for the HYDRA device (1.84 ± 1.40 mm,
range = 0.54–5.41mm) and the AeroNeb Go® (3.07 ± 1.56 mm, range = 0.86–10 mm).
Aerosolized palivizumab was delivered to the lungs at 88.79–94.13% of the total aerosolized
amount for all lambs, with a small proportion localized to either the trachea or stomach. No
difference between devices were found. Pulmonary deposition ranged from 6.57 to 9.25% of
the total dose of palivizumab loaded in the devices, mostly in the central right lung.in.org August 2020 | Volume 11 | Article 12911
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suggesting a promising approach in the control of severe RSV lung infections.Keywords: respiratory syncytial virus, lamb model, prophylactic, monoclonal antibody, palivizumab, nebulizationINTRODUCTION
Respiratory syncytial virus (RSV) is the leading pathogen causing
lower respiratory tract infections (O’Brien et al., 2019), and has
been responsible for up to 199,000 deaths worldwide in children
under 5 years old annually (Nair et al., 2010). Since 2013, the
World Health Organization has designated protection against
severe RSV disease as a high priority, particularly for infants <6
months of age, preterm infants, and infants with underlying
comorbidities. There is no vaccine available, and palivizumab, a
humanized monoclonal antibody (mAb) against RSV F protein, is
currently the only licensed preventive product but is costly, limited
in effectiveness and requires monthly intramuscular injections.
Inhaled delivery is one approach to provide pain- and needle-free
administration of palivizumab. It also offers the advantage of
delivering the mAb immediately and directly to the respiratory
tract and lung, potentially providing a rapid clinical benefit for the
prevention and/or treatment of severe RSV infection. Our recently
developed acoustic nebulizer, HYDRA (HYbriD Resonant
Acoustics) (Rezk et al., 2016) allows for fast and effective aerosol
delivery of mAbs (Cortez-Jugo et al., 2015) and other large biological
molecules such as DNA (Rajapaksa et al., 2014) to the respiratory
surface via inhalation. Using a lamb model, we compare the
deposition of aerosolized palivizumab to the lungs using the
HYDRA or the commercially-available AeroNeb Go® (now
marketed as Innospire Go by Philips Respironics) vibrating mesh
nebulizer as a proof-of-concept approach for the prevention and/or
treatment of severe RSV disease.
MATERIALS AND METHODS
Laser diffraction (Spraytec®, Malvern Instruments, Malvern, UK)
was employed to determine the aerodynamic diameter (Dae) of the
aerosols produced using the HYDRA or the AeroNeb Go®
(Aerogen, Galway, Ireland), from which the median aerosol size
(Dv50) was calculated from a volume-based size distribution. The
geometric standard deviation (GSD) was manually calculated
using standard methodology (Finlay, 2019).
The lamb study was approved by the Murdoch Children’s
Research Institute (MCRI) Animal Ethics Committee. Experiments
were designed and reported with reference to the ARRIVE (Animal
Research: Reporting of in vivo Experiments) guidelines (Kilkenny
et al., 2010). Fourmonth-old lambs were given 60mg of palivizumab
(Synagis®, AbbVie, Illinois, USA) at 10 mg/ml, conjugated to a
radiotracer technetium-99m (Tc-99m; Global Medical Solutions,
Tullamarine, Australia). 99mTcO4-palivizumab was prepared by a
ligand exchange method using glucoheptonate and tin chloride
(SnCl2). Briefly, 1 ml of palivizumab (100 mg/ml) was diluted in
1 ml water for injection, then incubated at room temperature with
150 ml of 2-mercaptoethanol for 20 min, before purification through
a PD-10 size exclusion column (30,000 MWCO). To this purifiedin.org 2eluent, 100 ml of glucoheptonate/SnCl2 stock (0.2 M glucoheptonate,
0.002 M SnCl2) solution was added and mixed. Roughly, 0.5 MBq of
99mTcO4was then added to the palivizumab/glucoheptonate solution
and incubated for 30 min at room temperature. Purity was checked
using the iTLC-SG method in water, before final dilution of the
conjugate to 10 ml (10 mg/ml palivizumab).
Palivizumab aerosols were delivered via an endotracheal tube
(Smiths Medical, Minnesota, USA) to spontaneously breathing
lambs (n = 2 lambs for each device) under anesthesia placed
in prone position. Pulmonary deposition was mapped using
single-photon emission computed tomography and computed
tomography (SPECT/CT) using a Symbia Intevo 16 scanner
(Siemens, Munich, Germany).
Lambs were placed in the prone position for this procedure.
SPECT portions of the scans were performed using the following
SPECT parameters: 128 × 128 matrix, 1.23× zoom, Tc-99m NMG
camera pre-set, 25 s per view for 64 views using a 180° detector
rotation and continuous scan mode. CT portions of the scans were
performed following topogram Scout view and imaged at 20mA
and 80kV. Image slices of 3 mm thickness were reconstructed using
a I50s Medium Sharp kernel with a lung window. Pre- and post-
delivery radioactive counts were measured to determine efficiency of
the aerosolized palivizumab administration. Briefly, for the SPECT/
CT analysis, lung structure segmentation was performed using
morphological watersheds with manually placed seeds applied to
the gradient of the CT image. Regional distribution of pulmonary
deposition was determined by voxelwise summation within each
lung structure. The efficiency of palivizumab delivery to lambs
relative to the total palivizumab prepared and the efficiency of
palivizumab delivery to the lungs relative to the whole body are
presented as geometric means (%). A RSV neutralization assay (Do
et al., 2019) was used to determine the bioactivity of palivizumab
before and after aerosolization.
RESULTS
Efficiency of palivizumab conjugation to Tc-99mwas >90% (Table
1). The median aerosol droplet diameter for palivizumab were
similar for both the HYDRA device (1.84 ± 1.40 mm, range = 0.54–
5.41 mm) and the AeroNeb Go® (3.07 ± 1.56 µm, range = 0.86–10August 2020 | Volume 11 | Article 1291TABLE 1 | Conjugation efficiency of palivizumab conjugated to technetium-99m
(Tc-99m).
Lamb Device % palivizumab deposited in lungs
Reading 1 Reading 2
1 AeroNeb Go® 98.51 98.33
2 AeroNeb Go® 97.94 91.75
3 HYDRA 94.83 90.32
4 HYDRA 99.09 98.41
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FIGURE 1 | Aerosolization and pulmonary deposition of palivizumab in lambs. (A) Reconstructed SPECT/CT images are shown for lambs 1 and 2 administered
palivizumab using AeroNeb Go® and lambs 3 and 4 using the HYDRA device. The trachea (T) and stomach (S) were also visible in some deposition images.
(B) Volume frequencies of the palivizumab aerosol size at given aerodynamic diameters for the AeroNeb Go® (light bars, dotted lines) and HYDRA device (dark bars,
solid lines). (C) Lungs were segmented into left apical (1), left caudal (2), right apical (3), right middle (4), and right caudal (5) lobes as shown. (D) Regional deposition
patterns of aerosolized palivizumab in individual lambs relative to the whole lung. (E) Concentration of palivizumab aerosols (counts/mm3) are shown within individual
lobes. Values on the intensity scale correspond to palivizumab density (counts per voxel).
Rajapaksa et al. Pulmonary Deposition of Radionucleotide-Labeled Palivizumabmm) nebulizers, producing palivizumab aerosols in the 1–5 µm
range that is optimal for deep lung deposition (Figure 1A). The
RSV neutralizing activity of conjugated palivizumab before and
after aerosolization was similar to native palivizumab and
comparable between the devices (Table 2).
Analyses of pulmonary deposition data from the SPECT/CT
images showed the percentage of total aerosolized palivizumab
delivered to the lambs (relative to that loaded to the devices)
ranged from 6.57 to 9.25% (Table 2 and Figure 1B). A large
percentage of the palivizumab aerosols (88.79–94.13%) was
deposited in the lungs (Table 1) with only a small proportion
localized to either the trachea or stomach. A similar level of
deposition was found for both devices (Table 2). Regional
deposition bias was demonstrated towards the left lung for
lamb 1 and the right lung for all other lambs, with deposition
detected across all five lung segments (Figures 1C–E; see also the
Supplementary Videos).DISCUSSION
This is the first study, to our knowledge, to explore the
pulmonary deposition of aerosolized palivizumab. We used
SPECT/CT as it is superior to planar imaging by providing a
three-dimensional assessment of aerosol deposition, allowing
determination of intrapulmonary distribution and precise
anatomical regional measurements. We were able to accurately
visualize palivizumab deposition in the lungs of all four lambs
regardless of the aerosolization device employed, providing
proof-of-concept for aerosol delivery of a RSV-specific mAb to
the potential sites of RSV replication.
Both the AeroNeb Go® and HYDRA devices showed similar
aerosol deposition in the lungs relative to the whole body,
without detriment to the palivizumab activity. The HYDRA
can potentially generate smaller particle size distributionsFrontiers in Pharmacology | www.frontiersin.org 4without the requirement of a mesh but we used a slightly
reduced nebulization rate compared with Aeroneb Go® for
large biomolecules such as palivizumab.
While significant loss of palivizumab due to deposition in the
endotracheal tube was observed, we do not expect the tube to
have any impact on the differences observed. In three lambs, we
noticed a depositional bias towards the right lung, with two of
these lambs showing higher deposition efficiency in the right
upper lobes in contrast to the other lamb which had higher
deposition in the lower left lobe. Several factors may explain the
difference observed in lamb 1: (1) maintaining procedural
anesthesia while receiving brief periods of manual ventilation
and (2) scheduling differences with the BALF procedure (2 weeks
earlier due to technical difficulties) could have induced fluid bias
to the right lung. A possible explanation might be that the
infusion of saline into the lung cavity during BALF collection
promoted increased humidity in the respiratory tract, which has
been shown to alter aerosol size and movement patterns (Cheng,
2014). As such the humid conditions of the right lung may have
attracted more aerosols into the respective lobes.
Targeting the lungs is proving to be an effective strategy as this
is the site of RSV infection (Davis et al., 2007). Recently, an anti-
RSV nanobody ALX-0171 at 0.3 mg/kg dose was aerosolized using
the AeroNeb Solo® system; whereby 11% of the therapeutic
nanobody was delivered to the lungs of RSV-infected lambs
leading to reductions in both RSV lesions and viral antigen
expression (Mora et al., 2018). In our study, the concentration
of palivizumab delivered to the lungs as a single dose (~0.57–0.85
mg/ml) was 2–4 fold greater than that shown previously to
neutralize RSV activity in vitro (Carlin et al., 1999). Aerosolized
palivizumab also appeared to cause low-level inflammatory
responses in the lung following delivery (data not shown) but
interpretation of this finding is difficult as we did not have a
control lamb without aerosolized palivizumab. Future studies are
therefore necessary to fully document these effects.
Conventional delivery of palivizumab via intramuscular (IM)
injection takes 3–5 days to achieve the dose in serum needed to
protect against RSV infections (Sáez-Llorens et al., 1998). Rapid
airway delivery of palivizumab may have substantial therapeutic
benefits for high-risk infants and may provide more targeted
control of RSV nosocomial infections in neonatal intensive care
units (NICU) compared to IM palivizumab previously used for
this purpose (Abadesso et al., 2004).
Despite the small sample size, this proof-of-concept study
provides important data on the feasibility of pulmonary delivery
and neutralizing bioactivity of palivizumab directly to the potential
site of infection. This concept could also be tested on the new
extended half-life RSV FmAb product (nirsevimab) that has recently
been granted Breakthrough Therapy Designation by the US Food
and Drug Administration (FDA). The lungs of a lamb constitute aTABLE 2 | Efficiency of aerosolized palivizumab delivery using the AeroNeb Go®
and HYDRA devices.












3 HYDRA 11.39 ± 0.1a NDb 94.13
4 HYDRA 6.57 92.51Data shown for individual lambs.
NAb, neutralizing antibody; ED50, titre of antibody that neutralises 50% of RSV infection;
aMean (± SD) NAb titre of native palivizumab stock (15.45 ± 0.3); bND, not determined due
to failure in taking pre-aerosolization measurements in one portion of the SPECT scanner.August 2020 | Volume 11 | Article 1291
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a human infant, including structure and function. Determining the
effect of inhaled palivizumab on RSV disease as well as the optimal
inhaled dose/schedule necessary to prevent the potential emergence
of RSV resistant strains are important next steps in the evaluation of
this novel delivery strategy.
Demonstrating the efficacy of regional lung deposition of
aerosolized palivizumab in a relevant model of human RSV
infection would be valuable to explore its therapeutic potential. If
successful, this strategy could be translated to high-burden
settings where 99% of RSV-related deaths occur.DATA AVAILABILITY STATEMENT
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